Personalized Addiction Treatment Enhancement for Opioid Use Disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests a digital health platform called Vira, delivered by peer recovery support specialists, for individuals prescribed buprenorphine or methadone. Participants are adults with a current opioid use disorder who have access to a smartphone. The trial compares the digital platform plus treatment-as-usual to treatment-as-usual alone to see if engagement and treatment outcomes improve. Eligibility requires English fluency, recent initiation or resumption of buprenorphine or methadone, and sufficient decision-making capacity. The study is led by Rhode Island Hospital with Ksana Health as a collaborator and is conducted at Rhode Island Hospital in Providence, RI.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 22+
* Current Opioid Use Disorder diagnosis
* Prescribed buprenorphine or methadone
* Initiated or reinitiated buprenorphine or methadone treatment recently
* Access to personal smartphone

Exclusion Criteria:

* Not fluent in English
* Limited mental capacity or inability to provided informed consent

Where it's running

• Rhode Island Hospital
  Providence, Rhode Island, United States Recruiting

Study contacts

• Principal investigator: Susan Ramsey, PhD — Rhode Island Hospital
• Study coordinator: Susan Ramsey, PhD
• Email: sramsey@brownhealth.org
• Phone: 401-444-7831

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CBD for Opioid Dependence and Pain on Buprenorphine

  This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.

  Recruiting Early Phase 1 Yale University · West Haven, Connecticut · NCT07886606

• Cebranopadol for opioid withdrawal in adults with chronic pain

  This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.

  Recruiting at 2 sites Phase 2 Adneuris Therapeutics, Inc. · North Canton, Ohio and 1 other locations · NCT07874620

• emPath platform pilot to link and keep adults with opioid use disorder in care in Durham

  This pilot tests a mobile app and telemedicine approach to help adults with opioid use disorder start and stay in MOUD through community outreach in Durham, NC.

  Recruiting Duke University · Durham, North Carolina · NCT07810322

• CB1 Receptors in Opioid Use Disorder Measured with a PET Radioligand

  This study tests CB1 receptor availability in people with opioid use disorder starting opioid agonist therapy and compares them with healthy adults.

  Recruiting Phase 1 Yale University · New Haven, Connecticut · NCT07800520

• STORC: Training a support person plus patient navigation after birth

  We’re testing whether training a designated support person and using patient navigation after delivery helps people with opioid use disorder build recovery resources and stay in treatment.

  Recruiting Friends Research Institute, Inc. · Philadelphia, Pennsylvania · NCT07787039

• Connecting Loved Ones to Support and Empower Recovery

  A web-based program called KulaMind-Recovery tests whether guided online training, one-on-one coaching, and a community forum help loved ones support someone with a substance use disorder.

  Recruiting Rhode Island Hospital · Providence, Rhode Island · NCT07740395

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.